Heart drug safety check: does argatroban alter heart rhythms?
NCT ID NCT05740371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 4 study looked at whether the blood thinner argatroban causes heart rhythm changes (QTc prolongation) in 50 patients with stable coronary artery disease or unstable angina during angioplasty. Patients received argatroban by IV and had ECGs before and after the procedure. The main goal was to see if the QTc interval increased by more than 10 milliseconds, which could signal a risk for dangerous heart rhythms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Argatroban (a blood thinner given by IV)
What this could lead to
If successful, this could confirm that argatroban is safe to use during heart procedures without causing dangerous heart rhythm changes.
What could go wrong
This is a small, completed Phase 4 safety study with only 50 participants, so results may not apply to all patients. It does not test whether argatroban improves outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STABLE CORONARY ARTERY DISEASE CAD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Herz-Kreislauf-Zentrum Klinikum Hersfeld-Rotenburg
Rotenburg an der Fulda, Hesse, 36199, Germany
-
University Hospital Frankfurt
Frankfurt am Main, Hesse, 60590, Germany